Foresee Pharmaceuticals Achieves Landmark Success in Phase 3 Study of Leuprolide Mesylate for CPP Treatment Foresee Pharmaceuticals announces remarkable results from their Phase 3 Casppian study, showcasing impressive LH suppression in children with Central Precocious Puberty, with a six-month dosing schedule.

Foresee Pharmaceuticals Achieves Landmark Success in Phase 3 Study of Leuprolide Mesylate for CPP Treatment #Taiwan #Taipei #Foresee_Pharmaceuticals #leuprolide_mesylate #Central_Precocious_Puberty